South Africa is making a bold move to locally produce lenacapavir, a groundbreaking twice-yearly HIV prevention injection developed by Gilead Sciences, with support from Unitaid and United States Pharmacopeia (USP), a step that could transform access, strengthen Africa’s pharmaceutical independence, and accelerate the fight to end HIV on the continent by bringing production closer to those ...









